CureVac plans global late-stage COVID-19 vaccine trial in fourth quarter

Credit: REUTERS/KAI PFAFFENBACH

Germany's CureVac NV said on Tuesday it has started a mid-stage study testing its experimental coronavirus vaccine and plans to begin a decisive global trial with about 30,000 volunteers in the fourth quarter.

Adds trial details, background, shares

Sept 29 (Reuters) - Germany's CureVac NV CVAC.O said on Tuesday it has started a mid-stage study testing its experimental coronavirus vaccine and plans to begin a decisive global trial with about 30,000 volunteers in the fourth quarter.

The company's U.S.-listed shares rose 10% to $49.66 in extended trading.

CureVac has dosed the first patient with its experimental COVID-19 vaccine in the trial taking place in Peru and Panama and expects data on older adults in the fourth quarter.

The vaccine developer plans to start the global trial after data from the ongoing studies.

CureVac is among the many in the race to develop a vaccine for COVID-19, with rivals including Novavax Inc NVAX.O and AstraZeneca AZN.L already conducting late-stage trials of their potential vaccines.

CureVac bagged nearly $300 million in funding from the German government earlier this month to speed up work on its prototype COVID-19 vaccine and build capacity to produce it at scale.

(Reporting by Trisha Roy in Bengaluru; Editing by Sriraj Kalluvila)

((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6182 3635;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CVAC NVAX AZN

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More